<DOC>
	<DOCNO>NCT01194414</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group study compare efficacy safety subcutaneous ( sc ) versus intravenous ( iv ) administration tocilizumab participant moderate severe active rheumatoid arthritis . Participants randomize receive either tocilizumab 162 mg sc weekly plus iv placebo every 4 week , tocilizumab 8 mg/kg iv every 4 week plus sc placebo weekly double-blind period baseline Week 24 . The double-blind period follow 72-week open-label treatment switch sc iv administration . No placebo administer open-label phase . Participants continue stable dose disease-modifying antirheumatic drug ( DMARDs ) throughout study . Anticipated time study treatment 2 year .</brief_summary>
	<brief_title>A Study Compare Subcutaneous Versus Intravenous Administration RoActemra/Actemra ( Tocilizumab ) Participants With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult participant , ≥ 18 year age Rheumatoid arthritis ≥ 6 month duration , accord American College Rheumatology ( ACR ) criteria Swollen joint count ( SJC ) ≥ 4 ( 66 joint count ) , tender joint count ( TJC ) ≥ 4 ( 68 joint count ) screen baseline Inadequate response current DMARD therapy Permitted DMARDs must stable dose ≥ 8 week prior baseline Oral corticosteroid ( ≤ 10 mg/day prednisone equivalent ) NSAIDs ( maximum recommend dose ) must stable dose ≥ 4 week prior baseline Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization Rheumatic autoimmune disease RA Functional class IV ( ACR classification ) Diagnosis juvenile idiopathic arthritis ( JIA ) juvenile rheumatoid arthritis ( JRA ) and/or RA age 16 Prior history current inflammatory joint disease RA Intraarticular parenteral corticosteroid within 4 week prior baseline Previous treatment tocilizumab Active current history recurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>